SELECTBIO - RNAi and miRNA Biographies

Home

Agenda

Keynote Speakers

Register

Exhibition

Venue

Training Courses

Business Courses

Workshops

Identifying miRNA in Biofluids to be Applied as Robust Biomarkers for Disease, Toxicology or Injury Studies – The case of Minimally Invasive Colorectal Cancer Detection

Wednesday, 5 September 2012 at 10:00

Add to Calendar ▼2012-09-05 10:00:002012-09-05 11:00:00Europe/LondonIdentifying miRNA in Biofluids to be Applied as Robust Biomarkers for Disease, Toxicology or Injury Studies – The case of Minimally Invasive Colorectal Cancer DetectionSELECTBIOenquiries@selectbiosciences.com

Using LNA™ based Universal RT-PCR system, we have profiled microRNA in thousands of biofluid samples including blood plasma/serum and urine. Implementation of extensive sample and data QC procedures will support development of robust biomarkers in disease, toxicology and injury studies.

Peter Mouritzen, Vice President, Exiqon A/S

Peter Mouritzen, MSc, PhD, is Director of Product development at Exiqon Life Sciences. Exiqon Life Sciences develop molecular biology tools for LNA™ based detection of nucleic acids and functional analysis. In particular the miRCURY brand is a set of tools that support the entire workflow in miRNA research from sample preparation, over miRNA profiling with arrays and qPCR, including validation by qPCR and in situ hybridization, to functional analysis with LNA™ miRNA inhibitors.